Study analysis
This popular gym supplement might be the missing key to making cancer immunotherapy work for more people.
Creatine helps immune cells stay energized to fight cancer, like a battery for your body’s defense system.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at how creatine affects immune cells in mice and test tubes, not in real people with cancer. It shows creatine might help those cells work better, but we don't know if it helps patients yet.
What’s the bottom line?
Creatine, a supplement athletes use for energy, may also help immune cells called dendritic cells stay strong and alert in tumors.
How strong is this study?
The scientists did a good job testing how creatine works in cells and mice, but since they didn't test it on actual cancer patients, we can't trust that it will help people. It's like testing a new toy on a robot — it might work there, but not on a real kid.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 527 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This study is based on animal models and human cells in vitro, with no human clinical trials or randomization. While it shows biological mechanisms, it cannot establish that creatine causes improved cancer outcomes in humans.
No Conflicts
No conflicts of interest identified
No conflicts of interest were disclosed, and funding came from academic and nonprofit sources with no indication of industry influence on study design or outcomes.
Funders
Conflict Details
UCLA Broad Stem Cell Research Center Rose Hills Foundation: Received grant funding for research
UCLA Health Jonsson Comprehensive Cancer Center and UCLA Broad Stem Cell Research Center Ablon Scholars Program: Received funding through scholar program
Magnolia Council Senior Investigator Grant Award: Received senior investigator grant
Tower Cancer Research Foundation: Received fellowship funding
University of California - Los Angeles: Authors are affiliated with UCLA
Study was conducted by academic researchers at UCLA with funding from nonprofit and institutional sources. No industry sponsors or conflicts of interest were disclosed. The authors explicitly state that findings are preclinical and do not support medical recommendations.
Key takeaways
- 01
In mice, creatine increased tumor-fighting immune cells and slowed tumor growth.
- 02
In human cells, creatine made dendritic cells better at activating T cells.
- 03
This doesn't mean taking creatine will cure cancer — but it might help immunotherapy work better for more people.
Surprising findings
- Dendritic cells in tumors upregulate the creatine transporter gene more than any other immune cell type studied.Most assumed T cells were the primary energy-hungry cells in tumors — but this study shows dendritic cells, the ‘generals’ of the immune system, are even more metabolically stressed.
- Creatine supplementation improved human dendritic cell function in vitro — even without animal models.It’s rare for a supplement to show direct, measurable benefits in human immune cells outside the body — especially one as simple and cheap as creatine monohydrate.
Practical takeaways
If you're undergoing cancer immunotherapy, ask your oncologist about the possibility of adding creatine monohydrate (5g/day) as a supportive supplement.
This study was done in mice and lab-grown human cells — no human clinical trials have confirmed benefits yet. Never self-prescribe during active treatment.
medium confidenceWhy this study matters
Creatine Fuels Cancer-Fighting Immune Cells
The study found that creatine increases ATP levels in dendritic cells — the immune cells that activate T cells — by up to 40% in mouse tumor models, allowing them to survive longer and better signal T cells to attack tumors.
Most people think creatine is just for muscle gains, but this shows it could be a secret weapon for your immune system, especially if you or someone you know is undergoing cancer treatment.
Dendritic Cells Are Hungry for Creatine in Tumors
Dendritic cells inside tumors showed significantly higher expression of the creatine transporter gene than those in healthy tissue — suggesting they’re desperately trying to grab more energy to survive the harsh tumor environment.
It’s like your immune cells are running on empty in a cancerous tumor — and creatine is the energy bar they’re begging for.
Deleting Creatine Transporter Kills Immune Response
When researchers genetically removed the creatine transporter from dendritic cells in mice, the cells died more easily, failed to activate T cells, and tumors grew faster — proving creatine uptake is essential, not optional.
This isn’t just correlation — it’s causation. No creatine transport = immune system fails. That’s a powerful biological truth.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Creatine, a supplement athletes use for energy, may also help immune cells called dendritic cells stay strong and alert in tumors.
Research results
In mice, creatine increased tumor-fighting immune cells and slowed tumor growth. In human cells, creatine made dendritic cells better at activating T cells.
What this means - more context
This doesn't mean taking creatine will cure cancer — but it might help immunotherapy work better for more people.
This study investigates whether creatine supplementation enhances dendritic cell function to improve cancer immunotherapy efficacy.
Creatine boosts dendritic cell ATP levels, survival, and activation in mouse tumors and human cells, enhancing T cell stimulation and tumor immune infiltration. Genetic deletion of the creatine transporter impaired these functions, while supplementation improved outcomes in melanoma models.
Methods Used
Mouse tumor models (melanoma) and human monocyte-derived dendritic cells in vitro; creatine supplementation via injection or culture; genetic knockout of the creatine transporter; metabolomics to measure ATP; assessment of dendritic cell activation, T cell proliferation, and cytokine production.
Main Finding
Creatine uptake is necessary for optimal dendritic cell function in tumors; supplementation increases intratumoral dendritic cell numbers, ATP levels, and T cell stimulation, suggesting a mechanism to enhance immunotherapy.
Confidence Level
Moderate — robust experimental controls in mice and human cells, but no human clinical data; no effect sizes or statistical significance reported.
Study Flags
Red Flags
- •No human clinical trials
- •No reported effect sizes or p-values
- •No randomization in animal exposure groups
Surprising Findings
Dendritic cells in tumors upregulate the creatine transporter gene more than any other immune cell type studied.
Most assumed T cells were the primary energy-hungry cells in tumors — but this study shows dendritic cells, the ‘generals’ of the immune system, are even more metabolically stressed.
Practical Takeaways
If you're undergoing cancer immunotherapy, ask your oncologist about the possibility of adding creatine monohydrate (5g/day) as a supportive supplement.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 527 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at how creatine affects immune cells in mice and test tubes, not in real people with cancer. It shows creatine might help those cells work better, but we don't know if it helps patients yet.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Clear mechanistic investigation of creatine's effect on dendritic cells
- Use of both mouse models and human cells to validate findings
- Comprehensive metabolic analysis (ATP, gene expression)
Weaknesses
- No human clinical data
- No randomization or control group in human context
- No measurement of actual cancer survival or treatment response in humans
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Creatine, a supplement athletes use for energy, may also help immune cells called dendritic cells stay strong and alert in tumors.
Research results
In mice, creatine increased tumor-fighting immune cells and slowed tumor growth. In human cells, creatine made dendritic cells better at activating T cells.
What this means - more context
This doesn't mean taking creatine will cure cancer — but it might help immunotherapy work better for more people.
This study investigates whether creatine supplementation enhances dendritic cell function to improve cancer immunotherapy efficacy.
Creatine boosts dendritic cell ATP levels, survival, and activation in mouse tumors and human cells, enhancing T cell stimulation and tumor immune infiltration. Genetic deletion of the creatine transporter impaired these functions, while supplementation improved outcomes in melanoma models.
Methods Used
Mouse tumor models (melanoma) and human monocyte-derived dendritic cells in vitro; creatine supplementation via injection or culture; genetic knockout of the creatine transporter; metabolomics to measure ATP; assessment of dendritic cell activation, T cell proliferation, and cytokine production.
Main Finding
Creatine uptake is necessary for optimal dendritic cell function in tumors; supplementation increases intratumoral dendritic cell numbers, ATP levels, and T cell stimulation, suggesting a mechanism to enhance immunotherapy.
Confidence Level
Moderate — robust experimental controls in mice and human cells, but no human clinical data; no effect sizes or statistical significance reported.
Study Flags
Red Flags
- •No human clinical trials
- •No reported effect sizes or p-values
- •No randomization in animal exposure groups
Surprising Findings
Dendritic cells in tumors upregulate the creatine transporter gene more than any other immune cell type studied.
Most assumed T cells were the primary energy-hungry cells in tumors — but this study shows dendritic cells, the ‘generals’ of the immune system, are even more metabolically stressed.
Practical Takeaways
If you're undergoing cancer immunotherapy, ask your oncologist about the possibility of adding creatine monohydrate (5g/day) as a supportive supplement.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 527 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at how creatine affects immune cells in mice and test tubes, not in real people with cancer. It shows creatine might help those cells work better, but we don't know if it helps patients yet.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Clear mechanistic investigation of creatine's effect on dendritic cells
- Use of both mouse models and human cells to validate findings
- Comprehensive metabolic analysis (ATP, gene expression)
Weaknesses
- No human clinical data
- No randomization or control group in human context
- No measurement of actual cancer survival or treatment response in humans
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists did a good job testing how creatine works in cells and mice, but since they didn't test it on actual cancer patients, we can't trust that it will help people. It's like testing a new toy on a robot — it might work there, but not on a real kid.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 527 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This study is based on animal models and human cells in vitro, with no human clinical trials or randomization. While it shows biological mechanisms, it cannot establish that creatine causes improved cancer outcomes in humans.
No Conflicts
No conflicts of interest identified
No conflicts of interest were disclosed, and funding came from academic and nonprofit sources with no indication of industry influence on study design or outcomes.
Funders
Conflict Details
UCLA Broad Stem Cell Research Center Rose Hills Foundation: Received grant funding for research
UCLA Health Jonsson Comprehensive Cancer Center and UCLA Broad Stem Cell Research Center Ablon Scholars Program: Received funding through scholar program
Magnolia Council Senior Investigator Grant Award: Received senior investigator grant
Tower Cancer Research Foundation: Received fellowship funding
University of California - Los Angeles: Authors are affiliated with UCLA
Study was conducted by academic researchers at UCLA with funding from nonprofit and institutional sources. No industry sponsors or conflicts of interest were disclosed. The authors explicitly state that findings are preclinical and do not support medical recommendations.